CA3048546A1 - Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof - Google Patents

Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof Download PDF

Info

Publication number
CA3048546A1
CA3048546A1 CA3048546A CA3048546A CA3048546A1 CA 3048546 A1 CA3048546 A1 CA 3048546A1 CA 3048546 A CA3048546 A CA 3048546A CA 3048546 A CA3048546 A CA 3048546A CA 3048546 A1 CA3048546 A1 CA 3048546A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
amino
stereoisomer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3048546A
Other languages
English (en)
French (fr)
Inventor
Heng Xu
Xiaoguang Chen
Songwen LIN
Ming Ji
Jing Jin
Deyu WU
Chunyang WANG
Yuanhao LV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica, CAMS&PUMC
Original Assignee
Institute of Materia Medica, CAMS&PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62707834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3048546(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201611211589.5A external-priority patent/CN108239075B/zh
Priority claimed from CN201611214102.9A external-priority patent/CN108239076B/zh
Priority claimed from CN201611204309.8A external-priority patent/CN108239074B/zh
Application filed by Institute of Materia Medica, CAMS&PUMC filed Critical Institute of Materia Medica, CAMS&PUMC
Priority to CA3174865A priority Critical patent/CA3174865A1/en
Priority to CA3174890A priority patent/CA3174890A1/en
Publication of CA3048546A1 publication Critical patent/CA3048546A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3048546A 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof Pending CA3048546A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3174865A CA3174865A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical composition thereof
CA3174890A CA3174890A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and its use as a phosphatidylinositol 3-kinase (pi3k) inhibitor

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201611211589.5A CN108239075B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611214102.9A CN108239076B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611214102.9 2016-12-26
CN201611204309.8A CN108239074B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611211589.5 2016-12-26
CN201611204309.8 2016-12-26
PCT/CN2017/118771 WO2018121550A1 (zh) 2016-12-26 2017-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA3174865A Division CA3174865A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical composition thereof
CA3174890A Division CA3174890A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and its use as a phosphatidylinositol 3-kinase (pi3k) inhibitor

Publications (1)

Publication Number Publication Date
CA3048546A1 true CA3048546A1 (en) 2018-07-05

Family

ID=62707834

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3048546A Pending CA3048546A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
CA3174865A Pending CA3174865A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical composition thereof
CA3174890A Pending CA3174890A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and its use as a phosphatidylinositol 3-kinase (pi3k) inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3174865A Pending CA3174865A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical composition thereof
CA3174890A Pending CA3174890A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and its use as a phosphatidylinositol 3-kinase (pi3k) inhibitor

Country Status (7)

Country Link
US (3) US11534443B2 (cg-RX-API-DMAC7.html)
EP (3) EP4169918B8 (cg-RX-API-DMAC7.html)
JP (3) JP7077323B2 (cg-RX-API-DMAC7.html)
CN (1) CN110382490A (cg-RX-API-DMAC7.html)
AU (3) AU2017389818B2 (cg-RX-API-DMAC7.html)
CA (3) CA3048546A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018121550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169918B8 (en) * 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
CN114555588B (zh) * 2019-11-07 2024-08-06 南京正大天晴制药有限公司 作为axl抑制剂的喹唑啉类化合物
CN113620976B (zh) * 2020-05-09 2023-09-26 中国医学科学院药物研究所 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
TW202416953A (zh) * 2022-08-26 2024-05-01 日商衛材R&D企管股份有限公司 抗體藥物複合物
CA3223670C (en) 2023-03-30 2026-05-26 Sunstack, Llc Trestle

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008781B1 (ko) * 1993-08-05 1996-07-03 김하운 연소효율 증강장치
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
CN105283454B (zh) * 2013-04-12 2019-10-29 阿萨纳生物科技有限责任公司 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉
CN108239076B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
EP4169918B8 (en) * 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
CN108239075B (zh) * 2016-12-26 2021-07-02 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239074B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物

Also Published As

Publication number Publication date
AU2017389818B2 (en) 2022-04-07
AU2022202885B2 (en) 2022-10-13
EP4169917A1 (en) 2023-04-26
US11534443B2 (en) 2022-12-27
CN110382490A (zh) 2019-10-25
JP2022119853A (ja) 2022-08-17
EP3560921A1 (en) 2019-10-30
EP4169917B1 (en) 2025-07-30
EP4169918B1 (en) 2025-07-30
JP7384535B2 (ja) 2023-11-21
JP7384536B2 (ja) 2023-11-21
WO2018121550A1 (zh) 2018-07-05
JP7077323B2 (ja) 2022-05-30
EP3560921B1 (en) 2024-08-14
CA3174890A1 (en) 2018-07-05
AU2022202886B2 (en) 2023-04-13
US12508263B2 (en) 2025-12-30
JP2020503321A (ja) 2020-01-30
AU2022202885A1 (en) 2022-05-26
US20230113478A1 (en) 2023-04-13
US12508264B2 (en) 2025-12-30
US20210128559A1 (en) 2021-05-06
EP3560921A4 (en) 2020-07-29
US20230110550A1 (en) 2023-04-13
JP2022119852A (ja) 2022-08-17
EP4169918B8 (en) 2025-09-24
AU2017389818A1 (en) 2019-08-08
EP4169918A1 (en) 2023-04-26
AU2022202886A1 (en) 2022-05-26
CA3174865A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
ES2928169T3 (es) Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
CN110072865B (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
CN109369671A (zh) 作为Raf激酶和/或Raf激酶二聚体抑制剂的稠合三环脲类化合物
BR122014012788A2 (pt) derivados de pirimidina fundidos, seus usos, e composição farmacêutica para inibição da atividade de tirosina quinase
ES2714100T3 (es) Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
CN101679426A (zh) 9-(吡唑-3-基)-9H-嘌呤-2-胺和3-(吡唑-3-基)-3H-咪唑并[4,5-b]吡啶-5-胺衍生物和它们治疗癌症的用途
CN114728945A (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
ES2701087T3 (es) Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis
CN108239074B (zh) 喹唑啉类化合物及其制备方法、用途和药物组合物
JP2025535057A (ja) フェニルオキシアミドキナーゼ阻害剤
ES2782113T3 (es) Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
CN108239075B (zh) 喹唑啉类化合物及其制备方法、用途和药物组合物
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN108239076A (zh) 喹唑啉类化合物及其制备方法、用途和药物组合物
CN115448906A (zh) 一种2-苯胺基嘧啶类衍生物及其制备方法与应用
CN119431448A (zh) 一种卤代嘧啶衍生物及其在医药上的应用
TW202317572A (zh) 雜環大環化合物及其醫藥用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241031

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241031

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241031

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241113

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250704

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251015

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251015

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260707